A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

NCT03009344 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Interventions

DRUG: Tazemetostat

Sponsor

Eisai Co., Ltd.